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Abstract: Living on earth, we are exposed to ultraviolet (UV) light as part of the solar radiation. UVB spectrum light exposure 
contributes to the development of skin cancer by interacting with pyrimidine pairs to create lesions called cyclobutane pyrimidine 
  dimers. If these lesions are not removed by nucleotide excision repair, they often give rise to C to T transition mutations. Based on 
these observations, a bioinformatics approach was used to predict the vulnerability of human protein coding genes to UVB induced 
loss of function mutations. This data was used to evaluate in depth those genes associated with malignant melanoma. In addition, we 
­ demonstrate­a­method­of­genetically­engineering­genes­that­significantly­improves­resistance­to­UVB­loss­of­function­mutations.
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Introduction
Skin  cancers  are  the  most  common  primary  type 
of  cancer.  The  three  most  common  primary  types 
of  cutaneous  cancer  are  squamous  cell  carcinoma, 
basal  cell  carcinoma,  and  malignant  melanoma. 
  Melanoma is of particular interest since it tends to 
occur in younger adults, and has a relatively poor 
prognosis if metastasis has occurred.1 Human epide-
miological studies as well as lab animal experiments 
indicate that UV exposure is an important etiological 
factor in all three types of skin cancer.2
The spectrum of solar UV light can be divided by 
wavelength into UVA, UVB, and UVC. UVB spec-
trum light exposure is thought to explain 80%–90% 
of the mutagenic effects of sunlight.2 DNA sequence 
analysis has revealed the target and effect of UVB 
exposure, which has come to be known as the ‘UVB 
signature’ mutation.3 The targets of UVB in DNA are 
pyrimidine pairs containing cytosine, ie, CC, CT, or 
TC. Following UVB exposure, these pyrimdine pairs 
give rise to either C-.T point mutations or CC-.TT 
dinucleotide changes.2
The mechanism by which UVB exposure causes 
this pattern of mutagenesis is partially understood. 
UVB  energy  can  be  absorbed  by  pyrimidines  and 
can  result  in  two  new  intrastrand  covalent  bonds 
formed between adjacent pyrimdines.4 This structure 
is known as a cyclobutane pyrimidine dimer (CPD). 
How the CPD gives rise to the observed mutations is 
unclear. One model supposes that a DNA polymerase 
introduces the incorrect nucleotide when using the 
CPD  containing  strand  as  the  template.  Another 
model supposes that at least one of the cytosines in 
the CPD are methylated and that the CPD structure 
increases  the  basal  spontaneous  deamination  of 
5-methylcytosine to thymidine.2
However, not every CPD that forms will necessar-
ily give rise to a mutation. CPD’s create a   distortion 
in the DNA that can potentially be recognized by the 
nucleotide  excision  repair  (NER)  enzymes.4 These 
enzymes­can­excise­part­of­the­strand­­ flanking­a­CPD­
and use the complementary strand as a template to 
replace  the  excised  sequence.  The  importance  of 
this  repair  pathway  is  highlighted  by    Xeroderma 
  pigmentosum  patients  who  exhibit  increased  fre-
quency of skin cancers.2
To sum up, when cells are exposed to UVB, UVB 
signature  mutations  may  occur.3  If  these  genetic 
alterations perturb key regulators of the cell cycle or 
apoptosis, skin cancer may develop. Several genetic 
loci have been associated with malignant melanoma 
including Tumor Protein 53 (TP53), Cyclin-dependent 
Kinase 4 (CDK4), Cyclin-dependent Kinase Inhibitor 
2A (CDKN2A), Melanocortin 1 Receptor (MC1R), 
Microphthalmia-associated  Transcription  Factor 
(MITF), v-Kit Hardy-Zuckerman 4 Feline Sarcoma 
Viral  Oncogene  Homolog  (KIT),  v-Raf  Murine 
Sarcoma  Viral  Oncogene  Homolog  B  (BRAF), 
Neuroblastoma  RAS  viral  Oncogene  Homolog 
(NRAS),  B-cell  Lymphoma  2  (BCL-2), Apoptotic 
Protease  Activating  Factor  1  (APAF1),  v-AKT 
Murine Thymoma Viral Oncogene Homolog (AKT), 
Phosphatase  and  Tensin  Homolog  (PTEN),  and 
FK506  Binding  Protein  12-Rapamycin  Associated 
Protein 1 (FRAP1).1
TP53 encodes the transcriptional regulator known 
as p53. Following genetic damage or other cellular 
stresses, p53 becomes stabilized and can arrest the 
cell cycle or induce apoptosis.5 Mutations in p53 are 
found in up to 5% of primary melanomas.6
CDK4  is  a  protein  kinase  that  phosphorylates 
Retinoblastoma  (Rb)  to  enable  G1-S  cell  cycle 
progression.7 Familial melanoma has been associated 
with lesions in CDK4.8 The CDKN2A locus encodes 
two isoforms involved in melanoma, p16INK4a and 
p14ARF.1  p16INK4a  binds  to  CDK4  and  inhibits 
cyclin D binding.9 Binding of p14ARF with Murine 
Double  Minute  2  (MDM2)  results  in  stabilization 
of  p53.5  Loss-of-function  mutations  in  CDKN2A 
cause increased CDK4 activity and a predispostion 
to malignant melanoma.1,8 Mutations in CDK2NA are 
the most common cause of familial melanoma, but 
can also occur sporadically.1
MC1R is a seven transmembrane G protein cou-
pled cell surface receptor for melanocyte-  stimulating 
hormone (MSH-alpha).10 Receptor activation results 
in  a  signaling  cascade  resulting  in  expression  of 
MITF  and  other  genes  neccesary  for  eumelanin 
  synthesis.11  MC1R  polymorphisms  are  associated 
with melanoma.12 MITF is a transcription factor that 
is  a  master  regulator  of  melanocyte  development, 
survival and melanogenesis.13­Amplification­of­MITF 
has been found in melanoma.14
The tyrosine kinase KIT is required for the develop-
mental migration and proliferation of   melanocytes.15 
Upon  binding  its  ligand  Stem-cell  Factor,  KIT UV sensitivity of human genes in cancer
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  activates a mitogen-activated protein kinase (MAPK) 
signaling cascade.16 Activating lesions in KIT have 
been reported in melanoma.17
NRAS is a member of the RAS family of plasma 
membrane  bound  small  G  proteins  that  can  be 
activated by receptor tyrosine kinases.18 When in its 
GTP bound form, RAS can activate RAF.19 RAF is 
a protein kinase that is part of a MAPK signaling 
cascade that promotes cellular proliferation.20 NRAS 
is  mutated  in  33%  of  primary  melanomas,  and 
associated with increased activity.18 BRAF is mutated 
in about two thirds of melanomas, typically causing 
increased activity.1
BCL-2 is primarily found in the outer membrane 
of  mitochondria  where  it  acts  to  prevent  release 
of  apoptosis  mediators  from  the  mitochondrial 
intermembrane space.21 The expression of BCL-2 may 
correlate  with  melanoma  progression  and  BCL-2 
antisense  therapy  has  been  shown  to  increase 
melanoma chemosensitivity in a mouse model.22,23
APAF1 forms apoptosomes with cytosolic cyto-
chrome c.24 This complex activates caspase-9, result-
ing in programmed cell death. APAF1 may undergo 
loss of heterozygosity as well as decreased expression 
due to methylation in melanoma.25
PTEN  encodes  a  lipid  and  protein  phosphatase 
that regulates levels of phosphatidylinositol (3,4,5)-
triphosphate  (PIP3)  by  dephosphorylation.26  Thus, 
decreased PTEN activity causes an increase in PIP3. 
PIP3 recruits the serine/threonine protein kinase AKT3 
to the cell membrane where it is becomes activated.27 
Through  phosphorylation  of  various  substrates, 
AKT3 inhibits apoptosis.27 AKT3 activity is increased 
in up to 60% of nonfamilial melanomas due to either 
increased copies of AKT3 or loss of PTEN.28
FRAP1,  also  known  as  mammalian  Target  of 
Rapamycin (mTOR), is a protein kinase that is found 
in  two  different  complexes  called  mTORC1  and 
mTORC2.29 mTORC1 promotes protein translation, 
favoring cell proliferation.29 mTORC2 activates AKT 
by phosphorylation.29 Increased mTOR activity was 
observed in 73% of melanomas.30
Despite the known importance of UVB sites in 
the  etiology  of  skin  cancers,  there  has  been  little 
work characterizing their distribution in the human 
genome. One goal of this work was to have a genome 
wide analysis of UVB sites with respect to coding 
sequences. Furthermore, we investigated the degree 
to  which  these  UVB  sites  would  be  deleterious  if 
mutated.  In  addition,  we  explored  the  relationship 
between UVB sites and genes implicated in malignant 
  melanoma.  One  supposition  is  that  these  coding 
sequences  would  have  an  overabundance  of  UVB 
sites that may predispose them to mutation. Another 
possibility is that the UVB sites found in these coding 
sequences are present in a sequence context that is 
more deleterious than that of the average gene.
Finally, we propose a novel approach for geneti-
cally  modifying  skin  cancer  susceptibility.  Given 
that UVB sites are the target of UVB   mutagenesis, 
decreasing  the  frequency  of  these  sites  should 
decrease the   susceptibility of a coding sequence to 
UVB   mutation. We propose a method for   decreasing 
the frequency of UVB sites while maintaining the 
wildtype primary amino acid sequence by the rational 
use of synonymous codon substitution. In this work, 
we  bioinformatically  predict  the  extent  to  which 
this method can improve UVB resistance of coding 
sequences.
Methods
An­ algorithm­ was­ developed­ which­ first­ identifies­
potential UVB sites in human protein coding sequences, 
individually  introduces  UVB  signature  mutations 
at these sites, and then predicts the consequence to 
the protein product. The UVB signature target site is 
defined­as­any­of­the­dinucleotides­CC,­CT,­and­TC­
(and GG, AG, and GA considering the change may 
occur on the complementary strand). The algorithm 
identifies­every­UVB­site­in­translated­exonic­genomic­
sequences. In addition, UVB sites may potentially 
be found at the junctions of exons, therefore, when 
extracting an exon from genomic sequence, we also 
took one additional nucleotide from each side of an 
exon in the analysis to not miss those instances where 
the­UVB­site­straddled­the­junction.­These­flanking­
nucleotides were trimmed after screening for UVB 
sites in the coding sequence.
The algorithm then individually creates a series 
of UVB single point mutants of the coding sequence 
by introducing single transition mutations (C-.T or 
G-.A) at each site. For CC and GG dinucleotide sites, 
there would be two separate single transition mutant 
sequences  generated.  In  addition,  UVB    doublet 
mutants of coding sequences were created at dinu-
cleotides CC (and GG considering the change may Lease and papageorgio
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occur on the complementary strand) by introducing 
two   transitions mutations (CC-.TT or GG-.AA). 
  Doublet mutants at CC and GG dinucleotides were not 
created if they straddled two codons (corresponding 
to­ phase­ 3­ position­ of­ the­ first­ codon­ and­ phase­
one position of the subsequent codon) because this 
information was already captured in the two single 
mutants created.
For  each  mutant,  the  BLOSUM62  amino  acid 
substitution matrix was then used to quantitatively 
assess the consequence of the altered codon when 
translated.31 BLOSUM62 uses a log odds ratio score 
and  awards  negative  scores  to  unfavorable  amino 
acid substitutions.32 The sum score for all unfavorable 
mutations for a gene was computed to get an   overall 
amino  acid  change  score  representing  the  UV 
  susceptibility  of  the  protein  coding  gene  (Fig.  1). 
A perl script was written to carry out this algorithm.
Version  37  of  the  human  genome  chromosomal 
genbank­flat­files­were­obtained­for­analysis­(http://
www.ncbi.nlm.nih.gov/Ftp/). A total of 32,357 coding 
sequences (CDS) were analyzed. 95 coding sequenes 
were  not  analyzed  because  they  were  incomplete 
fragments.­Due­to­our­inclusion­of­flanking­nucleotides­
in screening for UVB sites, the calculation of length of 
a coding sequence for the purpose of estimating UVB 
frequency,­was­defined­as­the­sum­of­all­coding­sequence­
nucleotides including the stop codon + 2 ⋅ (number of 
exons that contained coding sequence).
Genes  were  optimized  for  UVB  resistance  by 
selective  synonymous  codon  substitution.  The 
wildtype  primary  amino  acid  sequence  was  main-
tained  but  used  the  following  codons  substituted 
for the original codons: F = . TTT, L = . TTA, 
I = . ATT, M = . ATG, V = . GTA, S = . TCA, 
P = . CCA, T = . ACA, A = . GCA, Y = . TAT, 
STOP = . TAA, H = . CAT, Q = . CAA, N = . AAT, 
K = . AAA, D = . GAT, E = . GAA, C = . TGT, 
W = . TGG, R = . CGT, G = . GGT.
GC  percentage,  length,  and  dinucleotide  com-
position were calculated for each coding sequence. 
The output from the perl script was parsed into an 
Excel spreadsheet for ease of viewing. The data was 
imported  into  R  for  statistical  analysis  using  the 
  Bioconductor  package  multtest.33,34  P  values  were 
corrected for multiple measures using the Benjamini 
and Hochberg method.35 Mean GC percentage was 
calculated as the arithmetic mean of each CDS GC 
percentage.
Chi squared tests were used to estimate P values for 
observed number of UVB sites per CDS, as well as for 
observed frequency of UVB sites that were deleterious. 
The  expected  number  of  UVB  signature  sites  was 
calculated as the product of (0.3918 or 0.445)⋅ (length 
of CDS in nucleotides(nt) −1). The number 0.3918 
5’ ATG ACG ACT TCT ... 5’ ATA ACG ATT TTT 3’
3’ TAC
MT S T
TGC TGA AGA ...
...
... 3’ 5’
3’
TAT TGC TAA AAA 5’
II TF
11−1 −2
Unfavorable
BLOSUM62 total
amino acid change
score = −3
Figure  1.  Schematic  representation  of  algorithm  to  assess  UVB 
sensitivity. At left, boxes are drawn around UVB sites. Below the double 
stranded DNA is the single letter amino acid sequence for each codon 
of  the  upper  strand.  In  the  middle,  nucleotides  that  have  undergone 
  mutation are shown in bold. The translated sequence is shown below the 
DNA. The BLoSUM62 substitution matrix score for each new amino acid 
compared to its original amino acid is shown at the bottom. At right, the 
sum of the negative BLoSUM62 scores is given as the total amino acid 
change score for this sequence.
Table 1. UVB characteristics of human coding sequences.
Mean % of dinucleotides that are UVB  
sites (±SD)
  44.5% ± 5.2%
Mean % of UVB sites with single nt 
changes that were deleterious (±SD)
29.8 ± 5.8
Mean % of UVB sites with double nt 
changes that were deleterious (±SD)
67.9 ± 8.5
Mean amino acid change score per  
single nt deleterious mutation (±SD)
−2.16 ± 0.14
Mean amino acid change score per  
double nt deleterious mutation (±SD)
−2.69 ± 0.21
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Figure 2. Scatterplot of the number of UVB sites as a function of length of 
the coding sequence.UV sensitivity of human genes in cancer
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  double mutation being deleterious among all coding 
sequences.
To analyze average severity of single deleterious 
mutations,­a­control­sample­of­the­first­65000­negative­
BLOSUM62 single amino acid scores were collected 
from chromosome 5, which had a mean of −2.14. 
This set of scores was used for comparison of the 
single mutation negative scores from each melanoma 
related coding sequence two tailed Student’s t-test 
with equal variances.
Results
We  investigated  the  frequency  of  UVB  sites  in 
human coding sequences. At the outset, we expected 
UVB sites to be found 3/8 (or 38.75%) of the time 
for any dinucleotide of sequence considered. This 
assumption  was  based  on  probability  with  equal 
Table 2. Analysis of UVB site frequencies in the coding sequences of genes implicated in malignant melanoma.
Gene protein Observed expected P value
FRAP1 NP_004949.1 3344 3403.8 0.236
NRAS NP_002515.1 204 253.21 1.22E-04
AKT3 NP_859029.1 535 621.66 1.38E-05
AKT3 NP_005456.1 559 640.36 6.22E-05
MITF NP_937802.1 647 695.09 2.80E-02
MITF Np_006713.1 643 693.75 1.98E-02
MITF NP_937820.1 623 673.73 1.81E-02
MITF NP_937821.1 605 661.72 7.20E-03
MITF NP_000239.1 504 560.25 3.62E-03
MITF NP_937801.1 500 552.25 6.70E-03
KIT Np_000213.1 1122 1303.85 1.53E-10
KIT NP_001087241.1 1120 1298.51 3.11E-10
BRAF Np_004324.2 924 1023.5 1.11E-04
CDKN2A NP_000068.1 217 209.15 0.550
CDKN2A NP_478102.1 242 231.84 0.456
CDKN2A NP_478104.2 186 155.75 2.96E-03
PTEN NP_000305.3 417 538.89 2.32E-11
CDK4 Np_000066.1 421 405.39 0.381
APAF1 NP_863651.1 1425 1666.97 3.56E-14
APAF1 NP_863658.1 1378 1609.57 1.70E-13
APAF1 Np_037361.1 1415 1652.29 8.82E-14
APAF1 NP_001151.1 1368 1594.88 4.13E-13
APAF1 NP_863659.1 404 452.12 5.73E-03
TP53 NP_001119584.1 562 525.54 0.0576
TP53 NP_000537.3 562 525.54 0.0576
TP53 NP_001119587.1 365 349.32 0.340
TP53 NP_001119585.1 476 462.8 0.495
TP53 NP_001119589.1 279 286.58 0.626
TP53 NP_001119586.1 471 456.12 0.435
TP53 NP_001119588.1 274 279.91 0.707
BCL2 Np_000624.2 345 319.95 0.0978
BCL2 NP_000648.2 296 274.56 0.128
is the probability of a dinucleotide being a UVB site 
based  on  a  53.48%  GC  composition  and  random 
distribution. The number 0.445 is the probability of 
a dinucleotide being a UVB site based on the average 
UVB  frequency  among  all  coding  sequences.  The 
number of dinucleotides in a single stranded sequence 
is equal to the length in nt minus one.
The  expected  number  of  deleterious  single 
mutation sites in a CDS was calculated by multiplying 
the  number  of  UVB  sites  in  each  CDS  by  0.298. 
The  number  0.298  is  the  mean  frequency  of  a 
single mutation being deleterious among all coding 
sequences.
The  expected  number  of  deleterious  double 
mutation sites in a CDS was calculated by multi-
plying  the  number  of  CC  and  GG  UVB  sites  by 
0.679. The   number 0.679 is the mean frequency of a Lease and papageorgio
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frequency  (25%)  of  the  four  nucleotides.  This 
expectation­was­­ modified­based­on­the­average­GC­
composition  of  the    coding  sequences  of  53.48% 
to arrive at a 39.18% frequency of a UVB site at 
any given dinucleotide to be expected by chance. 
Interestingly, the observed mean frequency of UVB 
dinucleotides  among  all  coding  sequences  was 
44.5% ±­5.2%,­which­was­­ significantly­greater­than­
expected (P , 2.2E-16).
On average, only about 30% of the potential single 
transitions  would  result  in  an  unfavorable  amino 
acid  substitution  (Table  1).  Considering  doublet 
UVB mutations at positions 1–2 or 2–3 of codons, 
about 68% of these would give rise to unfavorable 
amino  acid  changes.  Unfavorable  mutations  at 
doublet  sites  also  tended  to  be  more  deleterious 
substitutions  with  a  mean  BLOSUM62  score 
of −2.69 per residue change compared to −2.16 at 
single unfavorable sites.
The  number  of  UVB  sites  in  human  coding 
sequences  could  be  important  for  susceptibility  to 
UVB mutagenesis. We counted the number of UVB 
sites in human coding sequences and observed that 
the number increases linearly as a function of the 
length of the coding sequence (R2 = 0.988) (Fig. 2). 
In addition, based on our model, the calculated amino 
acid change score grows more negative in a linear 
fashion with respect to length (R2 = −0.939) (data 
not shown). Thus, longer open reading frames are 
predicted to be more susceptible to UVB. However, 
neither the number of UVB sites nor the amino acid 
change score correlated with the GC percentage of 
Table 3. Frequency of single site UVB mutations being deleterious in the coding sequences of genes implicated in   malignant 
melanoma.
Gene protein Observed expected P value
FRAP1 NP_004949.1 812 978.63 4.69E-09
NRAS NP_002515.1 47 59.3 0.124
AKT3 NP_859029.1 147 133.8 0.292
AKT3 NP_005456.1 150 139.17 0.410
MITF NP_937802.1 175 185.36 0.505
MITF Np_006713.1 171 182.38 0.454
MITF NP_937820.1 165 177.31 0.406
MITF NP_937821.1 164 173.44 0.533
MITF NP_000239.1 135 143.34 0.547
MITF NP_937801.1 133 142.15 0.501
KIT Np_000213.1 317 302.77 0.470
KIT NP_001087241.1 316 302.17 0.484
BRAF Np_004324.2 311 254.49 1.93E-04
CDKN2A NP_000068.1 60 75.99 0.0719
CDKN2A NP_478102.1 105 81.95 9.62E-03
CDKN2A NP_478104.2 62 57.22 0.588
PTEN NP_000305.3 112 108.17 0.764
CDK4 Np_000066.1 123 122.48 0.972
APAF1 NP_863651.1 368 365.35 0.915
APAF1 NP_863658.1 356 350.45 0.813
APAF1 Np_037361.1 362 362.37 0.988
APAF1 NP_001151.1 350 347.47 0.916
APAF1 NP_863659.1 106 101.02 0.678
TP53 NP_001119584.1 193 163.01 1.79E-02
TP53 NP_000537.3 193 163.01 1.79E-02
TP53 NP_001119587.1 112 106.98 0.686
TP53 NP_001119585.1 171 138.57 4.73E-03
TP53 NP_001119589.1 90 82.55 0.468
TP53 NP_001119586.1 170 137.38 4.28E-03
TP53 NP_001119588.1 89 81.35 0.451
BCL2 Np_000624.2 115 111.45 0.785
BCL2 NP_000648.2 103 97.15 0.613UV sensitivity of human genes in cancer
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the coding sequence (R2 = −0.005 and R2 = −0.063) 
(data not shown).
We  investigated  whether  genes  associated  with 
malignant­melanoma­would­have­a­signficantly­dif-
ferent number of UVB sites than would be expected 
from  the  average  frequency  of  UVB  sites.  Seven 
of­the­genes­had­significantly­fewer­than­expected­
UVB­sites,­while­four­were­not­significantly­differ-
ent from the average gene. One isoform of CDK2NA 
was­found­to­have­a­significantly­increased­number­of­
UVB sites (Table 2).
It could be that a greater proportion of the UVB 
sites in genes implicated in malignant melanoma could 
give rise to deleterious substitutions if mutated. The 
predicted proportion of UVB site mutations causing a 
deleterious change was evaluated in the genes linked 
to malignant melanoma (Tables 3 and 4). A subset 
of­those­coding­sequences­did­have­a­significantly­
increased  proportion  of  sites  predicted  to  produce 
unfavorable changes, including four of seven coding 
sequences from TP53, one of the CDK2NA isoforms 
and BRAF. FRAP1 had a smaller proportion of sites 
that were unfavorable.
We  studied  whether  the  UVB  sites  in  cod-
ing  sequences  of  genes  implicated  in  melanoma 
would on average cause more deleterious changes 
than those found in the average coding sequence. 
This­ would­ be­ reflected­ by­ more­ negative­ BLO-
SUM62 scores. The predicted mean severity of UVB 
deleterious mutations was compared in genes linked 
Table 4. Frequency of deleterious double site UVB mutations in the coding sequences of genes implicated in malignant 
melanoma.
Gene protein Observed expected P value
FRAP1 NP_004949.1 374 406.04 0.0483
NRAS NP_002515.1 20 23.77 0.41952
AKT3 NP_859029.1 57 53.64 0.66931
AKT3 NP_005456.1 60 56.36 0.6467
MITF NP_937802.1 97 86.23 0.18206
MITF Np_006713.1 90 82.16 0.35182
MITF NP_937820.1 89 80.8 0.31838
MITF NP_937821.1 89 80.8 0.31838
MITF NP_000239.1 70 63.83 0.41952
MITF NP_937801.1 68 62.47 0.47403
KIT Np_000213.1 143 136.48 0.58688
KIT NP_001087241.1 143 135.8 0.5377
BRAF Np_004324.2 130 124.94 0.67396
CDKN2A NP_000068.1 30 40.74 0.03377
CDKN2A NP_478102.1 51 55.68 0.5311
CDKN2A NP_478104.2 34 35.99 0.77353
PTEN NP_000305.3 46 40.74 0.38021
CDK4 Np_000066.1 59 57.72 0.89452
APAF1 NP_863651.1 136 126.97 0.39808
APAF1 NP_863658.1 131 122.22 0.40319
APAF1 Np_037361.1 135 125.62 0.37138
APAF1 NP_001151.1 130 120.86 0.37571
APAF1 NP_863659.1 46 40.74 0.38021
TP53 NP_001119584.1 107 92.34 0.05998
TP53 NP_000537.3 107 92.34 0.05998
TP53 NP_001119587.1 64 57.04 0.31334
TP53 NP_001119585.1 92 79.44 0.08774
TP53 NP_001119589.1 49 44.14 0.44857
TP53 NP_001119586.1 92 79.44 0.08774
TP53 NP_001119588.1 49 44.14 0.44857
BCL2 Np_000624.2 65 68.58 0.69252
BCL2 NP_000648.2 58 61.11 0.72115Lease and papageorgio
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to   melanoma and a large control group (Table 5). 
Mutations  at  UVB  sites  in  the  coding  sequences 
of APAF1 and FRAP1­were­predicted­to­be­signifi-
cantly more deleterious.
Finally, we explored the use of rational synony-
mous codon substitution to alter the coding sequence 
without changing the primary amino acid sequence 
in  order  to  decrease  the  predicted  vulnerability  to 
UVB (Table 6). This method was found to decrease 
the number of UVB sites by almost 50% and improve 
the amino acid change score for the coding sequences 
of all genes associated with malignant melanoma by 
about 25%.
Discussion
Despite the importance of UVB sites in skin cancer 
formation,  the  extent  of  these  targets  and  their 
potential  for  deleterious  mutations  has  not  been 
previously investigated on a genome-wide basis. We 
found that these sites are quite prevalent in human 
coding­sequences­and­are­predicted­to­have­signficant­
deleterious potential. However, it was suprising that 
the majority of the time, the predicted consequence 
of  any  one  single  transition  mutation  at  a  UVB 
site is not unfavorable. It is interesting to note that 
the average coding sequence has more UVB sites 
than would be expected at random. This may be a 
consequence­of­codon­usage­biases­or­it­may­reflect­
an adaptive mechanism to facilitate UVB molecular 
mutation.
As UVB is a major causative factor in skin cancer 
and leads to UVB signature mutations, we hypothe-
sized­that­the­sequence­properties­of­genes­may­influ-
ence their likelihood to suffer from UVB induced loss 
of function mutations. That is, certain genes would 
have sequences that either contain more UVB   targets 
or the targets tend to occur in a more sensitive context 
that would lead to unfavorable mutations in either 
greater frequency or severity or some combination 
thereof.  Surprisingly,  most  genes  associated  with 
melanoma  have  a  fewer  than  expected  number  of 
UVB­sites.­This­may­reflect­a­selective­process­for­
these  genes  to  avoid  UVB  mutagenesis.  However, 
our data suggests that all three mechanisms may be 
at  play  depending  on  the  coding  sequence.  Some 
  coding sequences have an increased number of UVB 
sites,  some  have  an  increased  frequency  of  UVB 
sites that are deleterious and some tend to have more 
deleterious changes on average when mutated. These 
qualities may be useful in screening for additional 
genes important in melanoma, to identify additional 
diagnostic and therapeutic molecular targets.
Metastatic melanoma is associated with a 10 year sur-
vival rate of less than 10%.36 In addition, the frequency 
of melanoma is increasing and over 60,000 new cases 
occur each year in the United States.37   Therefore, the 
need for new methods for   primary   prevention of mela-
noma or in its treatment are greater than ever. We have 
described a new method for decreasing the suscepti-
bility of coding sequences to UV, much like sunscreen 
for genes. Although currently   preclinical, cutaneous 
Table 5. Mean severity of deleterious single mutations in 
the coding sequences of genes implicated in malignant 
melanoma.
Gene protein Mean 
severity
P value
FRAP1 NP_004949.1 −2.33 8.96E-05
NRAS NP_002515.1 −1.98 0.682
AKT3 NP_859029.1 −2.23 0.738
AKT3 NP_005456.1 −2.21 0.831
MITF NP_937802.1 −2.05 0.682
MITF Np_006713.1 −2.02 0.549
MITF NP_937820.1 −2.05 0.682
MITF NP_937821.1 −2.07 0.750
MITF NP_000239.1 −2.04 0.682
MITF NP_937801.1 −2.04 0.682
KIT Np_000213.1 −2.1 0.831
KIT NP_001087241.1 −2.1 0.831
BRAF Np_004324.2 −2.16 0.969
CDKN2A NP_000068.1 −2.15 0.979
CDKN2A NP_478102.1 −2.03 0.682
CDKN2A NP_478104.2 −2.19 0.960
PTEN NP_000305.3 −2.16 0.979
CDK4 Np_000066.1 −2.2 0.831
APAF1 NP_863651.1 −2.34 3.49E-03
APAF1 NP_863658.1 −2.35 2.56E-03
APAF1 Np_037361.1 −2.35 2.56E-03
APAF1 NP_001151.1 −2.36 2.56E-03
APAF1 NP_863659.1 −2.32 0.386
TP53 NP_001119584.1 −2.13 0.979
TP53 NP_000537.3 −2.13 0.979
TP53 NP_001119587.1 −2.11 0.965
TP53 NP_001119585.1 −2.14 0.995
TP53 NP_001119589.1 −2.11 0.969
TP53 NP_001119586.1 −2.14 0.979
TP53 NP_001119588.1 −2.1 0.965
BCL2 Np_000624.2 −2.2 0.831
BCL2 NP_000648.2 −2.2 0.831UV sensitivity of human genes in cancer
Cancer Informatics 2011:10  129
gene therapy has promise.38 As gene therapy advances, 
genetically  engineering  decreased  vulnerability  of 
a gene to UVB may be useful therapeutically in the 
treatment of this devastating disease.
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